Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer

Molecular Carcinogenesis

Volumn 50, Issue 12, 2011, Pages 931-944

  Kauffman, Eric C ^a   Robinson, Brian D ^a   Downes, Martin J ^b,c   Powell, Leagh G ^a   Lee, Ming Ming ^a   Scherr, Douglas S ^a   Gudas, Lorraine J ^a   Mongan, Nigel P ^a,c,d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Epigenetic; Histone lysine methylation; Urothelium

Indexed keywords

ANDROGEN RECEPTOR; ENZYME; JMJD2A PROTEIN; LYSINE SPECIFIC DEMETHYLASE 1; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; CYSTECTOMY; DEMETHYLATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SMOKING; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HISTONE DEMETHYLASES; HUMANS; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; NEOPLASM INVASIVENESS; PARGYLINE; RECEPTORS, ANDROGEN; TRANYLCYPROMINE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

NICOTIANA TABACUM;

EID: 80255137124     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20758     Document Type: Article

References (55)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Messing EM. Urothelial tumors of the bladder. In: Wein AJ, editor. Campbell-Walsh urology. Vol. 2. 9th edition. Philadelphia: Saunders Elsevier; 2007. pp. 2407-2446.
3. Shirodkar SP, Kishore TA, Soloway MS. The risk and prophylactic management of bladder cancer after various forms of radiotherapy. Curr Opin Urol 2009; 19: 500-503.
4. Herr HW, Faulkner JR, Grossman HB, et al. Surgical factors influence bladder cancer outcomes: A cooperative group report. J Clin Oncol 2004; 22: 2781-2789.
5. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: A contemporary series from the Bladder Cancer Research Consortium. J Urol 2006; 176: 2414-2422; discussion 2422.
6. Shariat SF, Palapattu GS, Karakiewicz PI, et al. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol 2007; 51: 152-160.
7. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1, 054 patients. J Clin Oncol 2001; 19: 666-675.
8. Madeb R, Messing EM. Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol 2004; 22: 86-92.
9. Tilki D, Svatek RS, Karakiewicz PI, et al. Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: A retrospective international study of 583 patients. J Urol 2010; 183: 87-93.
10. Bartsch GC, Kuefer R, Gschwend JE, de Petriconi R, Hautmann RE, Volkmer BG. Hydronephrosis as a prognostic marker in bladder cancer in a cystectomy-only series. Eur Urol 2007; 51: 690-697; discussion 697-698.
11. Sajjad Y, Quenby S, Nickson P, Lewis-Jones DI, Vince G. Immunohistochemical localization of androgen receptors in the urogenital tracts of human embryos. Reproduction (Cambridge, England) 2004; 128: 331-339.
12. Hartge P, Harvey EB, Linehan WM, et al. Unexplained excess risk of bladder cancer in men. J Natl Cancer Inst 1990; 82: 1636-1640.
13. Miyamoto H, Yang Z, Chen YT, et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 2007; 99: 558-568.
14. Johnson AM, O'Connell MJ, Miyamoto H, et al. Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: A role for thrombospondin-1. BMC Urol 2008; 8: 7.
15. Imada S, Akaza H, Ami Y, Koiso K, Ideyama Y, Takenaka T. Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats. Eur Urol 1997; 31: 360-364.
16. Okajima E, Hiramatsu T, Iriya K, Ijuin M, Matsushima S. Effects of sex hormones on development of urinary bladder tumours in rats induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. Urol Res 1975; 3: 73-79.
17. Tanahashi NK, Suzawa N, Azuma C. Effects of sex hormones on oncogenesis in rat urinary bladder by N-butyl-N-(4-hydroxybutyl)-nitrosamine. Int J Clin Pharmacol Biopharm 1977; 15: 101-105.
18. Boorjian SA, Heemers HV, Frank I, et al. Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocr Relat Cancer 2009; 16: 123-137.
19. Boorjian S, Ugras S, Mongan NP, et al. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology 2004; 64: 383-388.
20. Tuygun C, Kankaya D, Imamoglu A, et al. Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: A comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol Oncol 2009; 29: 43-51.
21. Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: A diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 2007; 28: 778-808.
22. Debes JD, Comuzzi B, Schmidt LJ, Dehm SM, Culig Z, Tindall DJ. p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res 2005; 65: 5965-5973.
23. Shi XB, Xue L, Zou JX, Gandour-Edwards R, Chen H, deVere White RW. Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells. The Prostate 2008; 68: 1816-1826.
24. Ligr M, Li Y, Zou X, et al. Tumor suppressor function of androgen receptor coactivator ARA70alpha in prostate cancer. Am J Pathol 2010; 176: 1891-1900.
25. Rahman MM, Miyamoto H, Takatera H, Yeh S, Altuwaijri S, Chang C. Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator ARA70 in prostate cancer cells. J Biol Chem 2003; 278: 19619-19626.
26. Marmorstein R, Trievel RC. Histone modifying enzymes: Structures, mechanisms, and specificities. Biochim Biophys Acta 2009; 1789: 58-68.
27. Metzger E, Wissmann M, Yin N, et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 2005; 437: 436-439.
28. Shin S, Janknecht R. Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D. Biochem Biophys Res Commun 2007; 359: 742-746.
29. Perillo B, Ombra MN, Bertoni A, et al. DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. Science (New York, NY) 2008; 319: 202-206.
30. Wissmann M, Yin N, Muller JM, et al. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol 2007; 9: 347-353.
31. Huang J, Sengupta R, Espejo AB, et al. p53 is regulated by the lysine demethylase LSD1. Nature 2007; 449: 105-108.
32. Lee MG, Wynder C, Cooch N, Shiekhattar R. An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature 2005; 437: 432-435.
33. Huang Y, Greene E, Murray Stewart T, et al. Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc Natl Acad Sci USA 2007; 104: 8023-8028.
34. Huang Y, Stewart TM, Wu Y, et al. Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin Cancer Res 2009; 15: 7217-7228.
35. Rose NR, Woon EC, Kingham GL, et al. Selective inhibitors of the JMJD2 histone demethylases: Combined nondenaturing mass spectrometric screening and crystallographic approaches. J Med Chem 2010; 53: 1810-1818.
36. Wilson JR. Targeting the JMJD2A histone lysine demethylase. Nat Struct Mol Biol 2007; 14: 682-684.
37. Yang M, Culhane JC, Szewczuk LM, et al. Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine. Biochemistry 2007; 46: 8058-8065.
38. Ueda R, Suzuki T, Mino K, et al. Identification of cell-active lysine specific demethylase 1-selective inhibitors. J Am Chem Soc 2009; 131: 17536-17537.
39. Lim S, Janzer A, Becker A, et al. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 2010; 31: 512-520.
40. Kahl P, Gullotti L, Heukamp LC, et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 2006; 66: 11341-11347.
41. Raman JD, Mongan NP, Liu L, et al. Decreased expression of the human stem cell marker, Rex-1 (zfp-42), in renal cell carcinoma. Carcinogenesis 2006; 27: 499-507.
42. -ΔΔCT method. Methods 2001; 25: 402-408.
43. Lee MG, Wynder C, Schmidt DM, McCafferty DG, Shiekhattar R. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem Biol 2006; 13: 563-567.
44. Zheng R, Shen R, Goodman OB, Jr., Nanus DM. Multiple androgen response elements cooperate in androgen regulated activity of the type 1 neutral endopeptidase promoter. Mol Cell Endocrinol 2006; 259: 10-21.
45. Mir C, Shariat SF, Van Der Kwast TH, et al. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: A large multi-institutional study. BJU Int 2010. DOI: 10.1111/j.1464-410X.2010.09834.x. [Epub ahead of print].
46. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A. Androgen receptor status of lymph node metastases from prostate cancer. The Prostate 1996; 28: 129-135.
47. Agoulnik IU, Weigel NL. Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem 2006; 99: 362-372.
48. Comuzzi B, Nemes C, Schmidt S, et al. The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer. J Pathol 2004; 204: 159-166.
49. Heemers HV, Sebo TJ, Debes JD, et al. Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res 2007; 67: 3422-3430.
50. Urbanucci A, Waltering KK, Suikki HE, Helenius MA, Visakorpi T. Androgen regulation of the androgen receptor coregulators. BMC Cancer 2008; 8: 219.
51. Niu Y, Altuwaijri S, Lai KP, et al. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA 2008; 105: 12182-12187.
52. Shen SS, Smith CL, Hsieh JT, et al. Expression of estrogen receptors-alpha and-beta in bladder cancer cell lines and human bladder tumor tissue. Cancer 2006; 106: 2610-2616.
53. Isidori AM, Lenzi A. Risk factors for androgen decline in older males: Lifestyle, chronic diseases and drugs. J Endocrinol Invest 2005; 28: 14-22.
54. Oefelein MG, Resnick MI. Association of tobacco use with hormone refractory disease and survival of patients with prostate cancer. J Urol 2004; 171: 2281-2284.
55. Butcher NJ, Tetlow NL, Cheung C, Broadhurst GM, Minchin RF. Induction of human arylamine N-acetyltransferase type I by androgens in human prostate cancer cells. Cancer Res 2007; 67: 85-92.